New Jersey
Pharmaceuticals Biotechnology and Life Sciences

Corporate Bias Rating

Expand Summary

Risk Level:

Rating - Danger
High Risk


Zoetis scored a 100 on the 2023 Corporate Equality Index (CEI) from the Human Rights Campaign (HRC), a political stakeholder group. By complying with the HRC’s controversial demands, Zoetis increases the risk of dividing employees, alienating customers and harming shareholders. The company covers transgender-related medical costs for its employees and their children and provides specific sexual orientation and gender identity-based benefits. It also uses sex and gender ideology criteria in employee recruitment, vendor selection, marketing, and philanthropic support. Zoetis forces employees to undergo multiple ideological trainings and uses its reputation, corporate funds, and political influence to support controversial sex and gender ideologies, organizations, and legislation. The company signed an open letter in support of the Equality Act and its CEO signed the CEO Action for Diversity and Inclusion pledge. Zoetis CEO is a member of the Business Roundtable and is a corporate partner of the National LGBT Chamber of Commerce (NGLCC). For these reasons, Zoetis receives a High Risk rating.

Generate Reports